Romosozumab joins the growing list of monoclonal antibody drugs that treat osteoporosis in postmenopausal women.
Kenny Walter
Advertisement
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Articles by Kenny Walter
In a dose finding trial, 100 μg of sprifermin every 6 or 12 months is proven to boost femorotibial joint cartilage thickness in patients suffering from osteoarthritis.
The monoclonal antibody class of drugs could help osteoporosis patients prevent fractures.
A combination of medication, vitamin D, and calcium, as well as physical therapy is necessary to treat osteoporosis.
In a new randomized study, investigators compare 2 hip surgeries for elderly patients with a displaced femoral neck fracture.
Investigators at CCR West find that kidney transplant patients commonly suffer from gout, even before the transplant.
In a small pilot study, investigators find medication non-adherence leads to more hospitalization of SLE patients.
In new data presented at CCR West, investigators link smoking and ethnicity with organ damage of SLE patients.
Biologics that target the immune system give doctors an opportunity to treat diseases like psoriasis and atopic dermatitis.
The new approval represents the third time the FDA approved the injection treatments for adults.
The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.
Advertisement
Advertisement
Advertisement